Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 14 2023 - 7:48AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2023.
Commission File Number: 001-39530
ImmunoPrecise Antibodies Ltd.
3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K is incorporated by reference into the Registration Statement on Form F-3 (File No. 333-273197) and Registration Statement on Form S-8 (File No. 333-256730) of the Registrant, ImmunoPrecise Antibodies Ltd.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
IMMUNOPRECISE ANTIBODIES LTD.
|
|
Date: December 14, 2023
|
|
|
|
|
|
|
|
By:
|
/s/ Kristin Taylor
|
|
|
Name:
|
Kristin Taylor
|
|
|
Title:
|
Chief Financial Officer
|
FORM 51-102F3
MATERIAL CHANGE REPORT
|
Item 1
|
Name and Address of Company
|
| |
|
|
|
ImmunoPrecise Antibodies Ltd. (the Company)
3204 4464 Markham Street,
Victoria, British Columbia, V8Z 7X8, Canada
|
| |
|
|
Item 2
|
Date of Material Change
|
| |
|
|
|
December 8, 2023
|
| |
|
|
Item 3
|
News Releases
|
| |
|
|
|
A news release with respect to the material change was disseminated by the Company on December 8, 2023 through Business Wire and subsequently filed on SEDAR+.
|
| |
|
|
Item 4
|
Summary of Material Change
|
| |
|
|
|
On December 8, 2023, the Company completed its previously announced sale of an aggregate of 1,265,000 common shares of the Company (each, a "Common Share") at a purchase price of US$1.00 per Common Share in an underwritten public offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules. The 1,265,000 Common Shares includes 165,000 Common Shares issued pursuant to the full exercise by an underwriter of its over-allotment option. The aggregate gross proceeds to the Company were approximately US$1.265 million, before the underwriters' discount and commissions for the facilitation of the Offering.
|
| |
|
|
Item 5
|
Full Description of Material Changes:
|
| |
|
|
|
On December 8, 2023, the Company completed its previously announced Offering of an aggregate of 1,265,000 Common Shares of the Company at a purchase price of US$1.00 per Common Share and priced at-the-market under the Nasdaq rules. The aggregate gross proceeds to the Company were approximately US$1.265 million, before the underwriter's discount and commissions for the facilitation of the Offering.
The Benchmark Company acted as the sole book-running underwriter and R.F. Lafferty acted as co-underwriter for the Offering.
The securities were offered and sold pursuant to a shelf Registration Statement on Form F-3 (File No. 333-273197) that was declared effective by the United States Securities and Exchange Commission (the "SEC") on July 14, 2023. A copy of the final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov.
No securities were offered or sold to Canadian purchasers.
|
| |
|
|
Item 6
|
Reliance on Section 7.1(2) of National Instrument 51-102
|
| |
|
|
|
Not applicable.
|
|
Item 7
|
Omitted Information
|
| |
|
|
|
Not applicable.
|
| |
|
|
Item 8
|
Executive Officer
|
| |
|
|
|
Jennifer Bath
Chief Executive Officer
(250) 483-0308
|
| |
|
|
Item 9
|
Date of Report
|
| |
|
|
|
December 13, 2023
|
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From May 2023 to May 2024
